SCHEMBL3884848

SCHEMBL3884848

Cc1ccc2cc(-c3ccccc3)c(C(=O)C(=O)Cl)n2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
THRB P10828 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.43
MAPT P10636 7/20 0.41
HTT P42858 3/20 0.41
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LMNA P02545 3/20 0.37
HDAC7 Q8WUI4 1/20 0.37
ALDH1A1 P00352 6/20 0.36
KMT2A Q03164 3/20 0.36
TDP1 Q9NUW8 3/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4434623 0.86 SMN1; SMN2 (0.49) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3883019 0.83 SMN1; SMN2 (0.46) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL1645256 0.81 LMNA (0.51) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3887651 0.81 SMN1; SMN2 (0.52) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3886744 0.81 SMN1; SMN2 (0.59) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL1645731 0.80 SMN1; SMN2 (0.68) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL3887478 0.76 SMN1; SMN2 (0.56) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL7171509 0.75 MAPT (0.39) SMN1; SMN2THRBL3MBTL1MAPTNPC1
SCHEMBL3884110 0.74 SMN1; SMN2 (0.44) SMN1; SMN2THRBL3MBTL1MAPTHTT
SCHEMBL1126731 0.74 MMP1 (0.41) SMN1; SMN2THRBL3MBTL1HDAC7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed
EP-1888063-A1 ANTIFUNGAL AGENTS F2G Ltd. (GB) 2008-02-20 EP disclosed
WO-2006123145-A1 ANTIFUNGAL AGENTS F2G LTD (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 SMN1; SMN2 3501/4885THRB 2955/4885L3MBTL1 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.